Axovant Gene Therapies

Pavan Cheruvu, M.D., CEO
New York, NY
(NASDAQ: AXGT)
Axovant Gene Therapies is a clinical-stage gene therapy company focused on developing a pipeline of innovative product candidates for debilitating neurodegenerative diseases. Our current pipeline of gene therapy candidates targets GM1 gangliosidosis, GM2 gangliosidosis (also known as Tay-Sachs disease and Sandhoff disease), and Parkinson’s disease. Axovant is focused on accelerating product candidates into and through clinical trials with a team of experts in gene therapy development and through external partnerships with leading gene therapy organizations.
www.axovant.com



By using this website you agree to accept our Privacy Policy and Terms & Conditions